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Summary Twenty-seven of 152 patients (18%) with progressing hormone resistant prostate cancer had
normal serum levels of prostate specific antigen (PSA < 1O jigl-), when referred for secondary treatment.
PSA was significantly correlated with the extent of skeletal metastases (R: 0.35) and the levels of hemoglobin
(R: -0.19) and serum alkaline phosphatase (R: 0.30).
In a multivariate Cox regression analysis the survival of the 152 patients was not correlated with the PSA
level but with the patients performance status, the level of hemoglobin, and the time between primary
hormone treatment and relapse.
The lack of serum PSA to predict survival may be explained by a heterogeneous composition of hormone
resistant prostate cancer as regards differentiated and/or PSA producing vs undifferentiated and/or PSA
non-producing cells.
Several authors have shown that prostate specific antigen
(PSA) mirrors the initial tumour burden and the develop-
ment of the disease during and after primary treatment of
prostate cancer (Emtage et al., 1987; Hetherington et al.,
1988; Stamey & Kabalin, 1989). The situation may be differ-
ent in hormone resistant patients. Until now, little attention
has been paid to the clinical role of PSA in such cases. The
present report attempts to assess the prognostic role of PSA
in patients with advanced prostatic cancer who are referred
to a cancer center for secondary treatment for progression of
their malignancy after primary androgen suppressive treat-
ment.
Patients and methods
The study comprises 152 consecutive patients referred to The
Norwegian Radium Hospital (NRH) during 1989 and 1990
for palliation treatment of symptomatic and progressing
cancer of the prostate with distant metastases (Table I). The
overwhelming majority of patients had undergone surgical
castration. The median interval between surgical or medical
castration and subsequent relapse (= hormone dependent
interval) was 17 months (2-225 months). A median time of 2
months had elapsed between the first symptomatic progres-
sion of the malignancy and referral to NRH (referral time).
Bone pain due to skeletal metastases was the most frequent
reason for referral and radiotherapy was the most frequent
secondary treatment (90 patients) at the NRH. Thirty-three
patients received additional systemic treatment such as Flut-
amide, cortico-steroids, Epi-Adriamycin or Mitomycin C.
Routine diagnostic work consisted of chest X-ray, 9'9Tc bone
scintigraphy (semi-quantitatively scored by the extent of the
disease [EOD] according to Soloway et al. [1988]) and hema-
tological and biochemical tests, including hemoglobin (Hgb),
creatinine, alkaline phosphatase (APHOS: upper normal limit
270 U 1-1) and PSA. Until May 1990 PSA was determined by
the Hybritech Tandem-PSA method, thereafter by a labora-
tory-developed IRMA (Waehre et al., 1991). All PSA values
were determined on the day of referral to the NRH before
any kind of investigational manipulation of the prostate was
performed. In this group of elderly patients the limit of the
upper normal range was set at 10 ig 1-' for both methods.
Computer tomographic examinations and ultra-sonography
were done only if clinically indicated. The primary tumour
was not assessed unless the patient had micturition problems.
On the basis of the PSA values the patients were grouped
as follows:
Group A: PSA< I0 lag I'
Group B: PSA 11-100ygl-l
Group C: PSA 101-500ptgl-'
Group D: PSA>500ligl-'
Most patients had no routine follow-up visits at the NRH
but were followed-up by their local hospital or by their
general practitioner who reported to the NRH on the deve-
lopment of the disease. For all patients the survival status per
1 September 1991 is known.
Table I Patient characteristics
Age and clerical course
Age (years)
Pre-relapse time (months)c
Hormone dependent interval (months)'
Referral time (months)'
Observation time (months)'
Primary treatment
Orchiectomy
Oestrogens
LH-RH antagonists
Performance status (WHO)
0/1
2
3
4
Bone scang [EOD]
0
2
3
4
Not done
70a (53 85)b
23 (2-225)
17 (2-225)
2 (0-52)
8 (0-43)
No. ofpts.
137
3
12
62
37
34
19
9
17
35
49
29
13
Laboratory tests Median (Range)
Hgb(gdl-') 12.1 (7.8-16.9)
APHOS (U 1-') 604 (109-10248)
PSA (jug Il') 131 (2-8194)
Creatinine (jtmol 1-') 88 (54-776)
aMedian; bRange; cTime from initial diagnosis to relapse; dTime from
castration to relapsae; 'Time from relapse to PSA measurement; 'From
PSA measurement; gAccording to Soloway et al.
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Statistics
Data analysis was performed by the PC based statistical
programme package Medlog (Information Analysis Corpora-
tion, Mountain View, CA 94040, USA, 1989) calculating
median, ranges and correlation coefficients (R) and perform-
ing the Wilcoxon test, Cox regression analysis and survival
analysis according to the Kaplan Meyer method. Differences
between survival curves were assessed by the log rank
method. A P value <0.05 was regarded as statistically
significant.
Results
Twenty-seven of the 152 patients (18%) had a PSA value
,10 fg 1' (Group A) at the time of referral to the NRH
and 32 patients presented with values> 500 fig l-
1 (Group D)
(Table II). With increasing PSA values there was a gradual
increase of APHOS and a reduction of Hgb, the correlation
coefficient being 0.30 and -0.19, respectively (P values
<0.05). Serum creatinine and performance status were not
correlated with PSA. As expected the distribution of EOD
scores was significantly different for the 4 groups. The PSA
values were significantly (P<0.001) correlated with the EOD
scores, though the correlation coefficient was only R = 0.35.
The shortest median hormone dependent interval was
measured for Group A, the longest for Group D without
significant difference of this parameter between the groups.
The median survival for all patients was 10 months from
referral to the NRH and PSA measurement with no signi-
ficant differences between the four groups (Figure 1). If
Group A was combined with Group D (Figure 2) the sur-
vival of Group (A + D) tended to be worse than that for the
combined Group (B + C) (P = 0.12).
The following parameters were analysed by the backwards
stepwise Cox regression analysis, as concern their impact on
survival: Performance status, Hgb, hormone dependent inter-
val, creatinine, PSA, APHOS, EOD score. Only the 3 first
variables proved to be significantly independent prognostic
parameters (P <0.002). The EOD score was a 4th almost
significant prognostic parameter (P = 0.10). The addition of
PSA to the three first mentioned parameters did not contri-
bute to a better prediction of survival (P = 0.20).
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Figure 1 Serum PSA levels and survival of 152 patients with
progressing hormone resistant prostate cancer with metastases.
PSA 10figl-' (Group A: 27 patients). --- PSA
1 1 -100fg I(Group B: 40 patients). PSA 101 -500fg I -'
(Group C: 53 patients). -.- PSA> 500 llg 1-' (Group D: 32
patients).
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Figure 2 Survival in patients from combined Group (A + D)
(0) vs Group (B + C) (0) (P: 0.12).
Table II Relation of serum PSA and clinical/biochemical parameters
Correl
Group A Group B Group C Group D coeff. (R) P
No of pts. 27 40 53 32
PSA(jg I l') 4a (2- 1O)b 42 (13-93) 190 (102-480) 992 (526-8194)
Hgb (gdl-') 12.6 (8.9-14.6) 123 (8.5-153) 11.7 (8.1-15.3) 11.4 (7.8-16.9) -0.19 0.02
APHOS (U1') 278 (134-1666) 367 (109-2166) 728 (124-10248) 893 (117-4974) 0.30 <0.01
Cr (jumol 1-') 88 (58-776) 90 (54-250) 85 (55-258) 89 (58-234) -0.04 0.67
Hormone dependent 12 (2-95) 18 (4-105) 16 (2-92) 22 (2-225) 0.10 0.21
interval (months)
Referral time 2 2 2 2 0.07 0.38
(months) (0-12) (0- 19) (0-11) (0-52)
Bonescan
0 4 4 1
1 10 4 3
2 6 15 9 5 0.35 <0.001
3 5 10 24 10
4 1 3 10 15
Missing 1 4 7 1
Performance status
0/1 14 17 21 10
2 6 9 15 7
3 2 10 14 8 0.11 0.17
4 5 4 3 7
aMedian; bRange.
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Discussion
Numerous investigations have demonstrated the correlation
of PSA and the initial tumour stage in prostate cancer
(Emtage et al., 1987; Hetherington et al., 1988; Stamey &
Kabalin, 1989; Stamey et al., 1989a; Stamey et al., 1989b;
Stamey et al., 1989c). Though some overlap exists, PSA
increases with increasing tumour stage. In contrast to the
considerable interest paid to PSA measurements in previously
untreated patients and during initial treatment, the present
study represents to the authors' knowledge the first report on
PSA measured in a larger series in patients with advanced
hormone resistant prostate cancer.
As many as 18% of the castrated men with advanced
prostate cancer had PSA (10 gl-1. This is in agreement
with Morgan et al. (1991) observations of low PSA values in
relapsing patients with prostate cancer treated with radical
prostatectomy and adjuvant hormone treatment. In Leo et
al.'s (1991) report as many as 45% of the hormonally treated
patients had PSA values < 10 ytg 1-'. Furthermore, in animal
studies the reduction of PSA during androgen-suppressive
treatment was found to be more pronounced than the
decrease of the tumour burden (Csapo et al., 1988). One
explanation for the limited correlation between PSA and
assessed tumour volume would be that the tumour manifesta-
tions in hormone resistant disease consist of relatively large
amounts of undifferentiated and probably PSA non-produc-
ing cells (Bruchovsky et al., 1987; Isaacs, 1984). Such a
finding might mirror a particularly aggressive tumour bio-
logy. The relative short hormone dependent interval (median
12 months) for Group A supports this view. Normal PSA in
hormone resistant prostatic cancer may thus be another sign
of high biological aggressiveness.
The relatively low coefficient of correlation between PSA
and skeletal EOD (R: 0.35) may be due to not-detected
tumour manifestations elsewhere in the patient. An individ-
ual patient with hormone resistant prostate cancer may pre-
sent with large soft tissue tumour masses which remain
undetected by routine examination (computer tomogrpahy
usually not performed), but contribute significantly to the
total tumour burden and probably to the individual's PSA
level.
The PSA level in a patient with hormone resistant prostate
cancer seems to be dependent on the balance of several
conditions: The often undetected true tumour burden and the
quantitative relation between PSA non-producing undiffer-
entiated cells and PSA-producing more differentiated cells.
Normal or only slightly elevated PSA values may reflect
limited disease or, as probably the case in most of our
patients, may be correlated with larger metastases from a
biologically aggressive and rapidly progressing cancer mainly
consisting of PSA non-producing cells. The latter patients
would theoretically have a similar prognosis as patients with
high PSA values usually correlated with extensive disease.
This was the background for comparison of the survival for
the combined Group (A + D) with that for Group (B + C),
where a tendency of improved prognosis was found for
Group (B + C). Leo et al. (1991) discuss a 3rd explanation
for low PSA levels in patients with short survival times.
Hormone treatment may decrease the cellular PSA expres-
sion without reducing the tumour cell's viability.
Due to the above heterogeneity of the internal composition
of tumour manifestations in hormone resistant prostate
cancer and the often unknown true tumour burden, patients'
survival seems better to be related to indirect parameters as
Hgb and performance status than to PSA, APHOS or bone
scan involvement. It is therefore understandable that the
former parameters represent independent prognostic para-
meters, whereas PSA does not. The time between the initial
hormone treatment and relapse (hormone dependent interval)
is another significant parameter, probably mirroring the bio-
logical aggressiveness of the individual tumour.
Also in other studies Hgb, performance status and hor-
mone control time have been found to be independent prog-
nostic parameters (Paulson et al., 1979; Berry et al., 1979;
Emrich et al., 1985; Manni et al., 1988). In one of our
previous studies also creatinine was a significant independent
parameter (Fossa et al., 1991). We have no explanation why
this parameter was not an independent parameter in the
present study except from noting a lower frequency of
patients with elevated creatinine, 11%.
In the present study about PSA the level did not have
prognostic value if measured shortly after symptomatic pro-
gression of prostate cancer. This does not exclude that PSA
measurements are without clinical significance in these
patients. Any larger PSA increase most likely mirrors disease
progression in spite of ongoing treatment and the degree of
increase may reflect the rate of progression, thus probably
bearing prognostic impact. This hypothesis cannot be tested
in the present patient series, as no PSA levels were available
prior to their admission to the NRH. Furthermore, most of
the patients were neither followed-up by the NRH nor had
PSA values after their palliative treatment at this instit-
ution.
In conclusion, in hormone resistant prostatic cancer serum
PSA levels are correlated with the bone scan involvement,
Hgb and APHOS, though the correlation coefficients are
relatively low. However, 18% of the patients had normal
serum PSA values in spite of advanced disease. PSA values
analysed about 2 months after subjective progression of hor-
mone resistant prostate cancer do not predict patients' sur-
vival.
This study was financially supported by the Norwegian Cancer
Society.
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